{"filings":[{"id":731956,"accession_number":"0001628280-26-039005","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-05-29T12:39:28+00:00","items":["7.01","9.01"],"status":"ready","headline":"BD resumes ChloraPrep shipments after voluntary hold; all final release testing acceptable","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["BD voluntarily placed ChloraPrep and PurPrep on ship hold on May 6, 2026 for additional final release testing.","Shipments of ChloraPrep have resumed in the U.S. after completion of additional assessments and testing.","All additional final release testing performed to date has been acceptable; no patient safety signals.","The ship hold was in response to the FDA Warning Letter for the El Paso manufacturing facility.","Detailed risks associated with the Warning Letter are described in BD's Q1 FY2026 10-Q filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":556556,"accession_number":"0001140361-26-022270","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-05-20T21:05:06+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"BD subsidiary issues €600M 3.855% Notes due 2033; proceeds to repay near-term debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€600M aggregate principal of 3.855% Notes due May 20, 2033 issued by BD indirect sub Becton Finance.","Notes are fully and unconditionally guaranteed by Becton, Dickinson and Company (BD).","Proceeds, plus cash, to repay entire €1.208% Notes due June 4, 2026.","Remaining net proceeds used for general corporate purposes.","Redemption at BD's option: before Feb 20, 2033 at make-whole +15 bps; after at 100%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":41244,"accession_number":"0001140361-26-020828","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-05-12T20:30:54+00:00","items":["8.01","9.01"],"status":"ready","headline":"BD launches €600M 3.855% notes due 2033 to refinance maturing Euro notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€600M aggregate principal of 3.855% Notes due 2033, guaranteed by BD.","Net proceeds, with cash on hand, to repay €1.208% Euro Notes due June 4, 2026.","Offering expected to close on or about May 20, 2026, subject to customary conditions.","Underwriters include Barclays, BNP Paribas, Goldman Sachs, Morgan Stanley."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91142,"accession_number":"0001628280-26-031638","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q2 FY2026 revenue $4.7B (+5.2% reported), GAAP EPS $(0.13), adj. EPS $2.90; raises FY adj. EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4,714M, +5.2% reported/2.6% FX-neutral; GAAP diluted EPS $(0.13) from continuing ops vs $0.55 prior year.","Adjusted diluted EPS $2.90, up from $2.79 (+3.9% reported); company raises full-year adjusted EPS guidance.","Executed $2.0B accelerated share repurchase and retired $2.1B of debt in the quarter.","Reaffirms revenue growth guidance; more than 90% of business delivered mid-single-digit growth.","Spin-off of Biosciences & Diagnostic Solutions completed Feb 9, 2026; results reflect continuing ops."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":9200000000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91138,"accession_number":"0001628280-26-031642","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K/A","filed_at":"2026-05-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BD appoints Vitor Roque as EVP and CFO effective May 7; compensation disclosed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roque named EVP and CFO effective May 7, 2026; served as interim CFO since December 2025.","Annual base salary $770,000; target bonus 95% of base; annual equity target $3M.","One-time cash award $250,000 and time-vested units $250,000 for interim service.","Severance agreement: 2x salary and bonus upon change of control, two-year term.","Roque led separation of Biosciences & Diagnostic Solutions ahead of schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91141,"accession_number":"0000010795-26-000012","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BDX board approves bylaw amendments updating advance notice provisions and technical revisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended and restated By-laws on April 28, 2026.","Changes update the advance notice provision's timeframe for determining a contested election.","Other technical, conforming, and clarifying revisions made; full text filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91140,"accession_number":"0001628280-26-024472","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BD EVP & Interventional President Richard Byrd to retire in June 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Byrd, EVP and President of Interventional segment, will retire after nearly 25 years at BD; will stay in role through June.","BD intends to name a successor prior to Byrd's retirement date; no replacement announced.","Byrd previously led Medication Delivery Solutions and Preanalytical Systems, and led manufacturing scale-up during COVID-19.","CEO Tom Polen cited Byrd's leadership in expanding Vascular Access Management and advancing 'One-Stick Hospital Stay' vision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91139,"accession_number":"0001628280-26-023185","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD files recast financials to reflect Feb 2026 spin-off of Biosciences & Diagnostics","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Recast historical data presents continuing operations only, excluding the spun-off Biosciences and Diagnostic Solutions business.","Spin-off completed Feb 9, 2026, with the business combined into Waters Corporation.","Non-GAAP financial measures are included in Exhibit 99.1 to assist investor analysis.","Recast provides a baseline for BD's standalone operating results from continuing operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101069,"accession_number":"0001140361-26-006794","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BD upsizes senior notes tender to $2B, announces early results and pricing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Upsized aggregate offer cap from $1.6B to $2.0B; early tenders exceeded cap, triggering proration on 3.794% notes due 2050.","Accepted ~$2.12B in principal across 15 series; 3.794% notes accepted on prorated basis at $262.7M.","Total Consideration per $1,000 principal ranged from $789.44 (3.794% notes) to $1,065.75 (6.700% debentures).","Early settlement scheduled for February 27, 2026; all conditions satisfied or waived."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101068,"accession_number":"0001140361-26-004601","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BD launches $1.6B tender offers for 15 series of senior notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $1.6B aggregate purchase price (excluding accrued interest) for 15 series of senior notes maturing 2026-2050.","Early tender deadline Feb 24, 2026; offers expire Mar 11, 2026; settlement expected Mar 13, 2026.","Early tenders receive fixed spread over UST benchmark plus $30 per $1,000 early tender payment.","Largest notes: 4.669% Senior Notes due 2047 ($1.5B outstanding) subject to $1B Offer SubCap.","Lead dealer managers: Citigroup and Wells Fargo; co-dealer managers: Scotia, MUFG, U.S. Bancorp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101067,"accession_number":"0001628280-26-006182","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q1 revenue $5.25B beats; closes Waters deal; affirms FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.252B (+1.6% reported, +0.4% FX neutral); GAAP EPS $1.34, adjusted EPS $2.91.","BD to close combination of Biosciences & Diagnostic Solutions business with Waters Corporation on Feb 9, 2026.","Affirms FY26 revenue growth guidance; provides New BD adjusted diluted EPS guidance.","Announced $110M investment for Neopak syringe production in Nebraska; FDA clearance for EnCor EnCompass biopsy system.","Adjusted diluted EPS $2.91, down 15.2% YoY on reported basis but beat expectations."],"consensus_eps_estimate":2.8027,"consensus_eps_actual":1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":5252000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101066,"accession_number":"0001193125-26-042827","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["1.01","5.02","7.01","8.01","9.01"],"status":"ready","headline":"BD completes spin-off of Biosciences & Diagnostic Solutions business and combination with Waters","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BD completed spin-off of Biosciences & Diagnostic Solutions business and combination with Waters, receiving $4 billion cash.","BD shareholders received 0.135 Waters shares per BD share, representing 39.2% ownership of combined company.","BD plans to use $2 billion for share repurchases and $2 billion for debt repayment.","Claire M. Fraser resigned from BD Board and appointed to Waters Board effective upon closing.","Transaction valued the spun-off business at $18.8 billion based on Waters closing price on Feb 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101065,"accession_number":"0001628280-26-005793","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BD reorganizes into five segments; provides recast historical revenue data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New segments effective Oct 1, 2025: Medical Essentials, Connected Care, BioPharma Systems, Interventional, Life Sciences.","Life Sciences segment to be eliminated after planned combination of Biosciences/Diagnostic Solutions with Waters Corp (announced July 13, 2025).","Exhibit 99.1 furnishes recast segment revenues for FY2025 and quarterly periods, including non-GAAP measures.","Segment reorganization does not affect principal product lines of any organizational unit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101064,"accession_number":"0001193125-26-039448","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["3.02","5.03","9.01"],"status":"ready","headline":"BDX files preferred stock designation for spin-off of Biosciences business; issues 27.5 Series D shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Filed Certificate of Designation for Series D Junior Participating Redeemable Preferred Stock.","Issued 27.5159 Preferred Shares to deferral plan trusts in exchange for 275,159 common shares at 1:10,000 ratio.","Exchange ensures trust holders do not receive SpinCo common stock in the planned Waters combination.","Preferred shares are redeemable for common stock; automatic redemption if spin-off closes.","Spin-off will combine Augusta SpinCo Corp. (Biosciences & Diagnostic Solutions) with Waters Corporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101063,"accession_number":"0001628280-26-004393","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BD adopts executive severance plan; shareholders approve equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Severance Plan adopted: CEO gets 1.5x base+bonus, ELT 1.0x, Business Unit Presidents 1.0x base.","Shareholders approved 3.935M share increase to 2004 equity plan; say-on-pay passed with ~91% support.","All 13 director nominees elected; auditor Ernst & Young ratified for FY2026.","Plan replaces prior severance policies; effective Jan 27, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101062,"accession_number":"0001193125-26-004659","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["5.04"],"status":"ready","headline":"BD 401(k) Plan enters blackout period pending Waters Corp transaction close","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Blackout begins after market close on closing date of pending Waters Corp transaction.","Blackout ends during the week following the closing date.","Plan participants cannot exchange into/out of BD Common Stock Fund, take loans or withdrawals during blackout.","Blackout scheduled to facilitate addition of Waters Common Stock Fund interests to Plan.","Contact Fidelity at 1-866-715-2068 for actual blackout dates or questions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117410,"accession_number":"0001628280-25-054447","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K/A","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BDX amends 8-K to disclose director compensation for Huffines and Wright","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert L. Huffines and Jacqueline Wright elected to BD Board, effective Dec 1, 2025.","Each receives restricted stock units valued at $33,575 (prorated grant to 2026 annual meeting).","Compensation consistent with non-management director program described in 2025 proxy statement.","Original 8-K filed Nov 17, 2025; this amendment adds compensation details previously unavailable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117413,"accession_number":"0001628280-25-052625","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BD elects Robert Huffines and Jacqueline Wright to board, effective Dec 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expands from 12 to 14 members; both new directors deemed independent under NYSE rules.","Wright will serve on Audit and Compensation Committees; Huffines on Audit and Governance/Nominating.","Both receive prorated restricted stock unit grants from Dec 1, 2025 to BD’s 2026 Annual Meeting.","No departure of existing directors; appointments are additive to board composition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117412,"accession_number":"0001628280-25-049835","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q4 revenue $5.9B (+8.3%); FY25 adjusted EPS $14.40 (+9.6%); FY26 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $5,890M, up 8.3% as reported, 3.9% organic; GAAP EPS $1.72, adjusted EPS $3.96.","FY25 revenue $21.8B (+8.2% as reported); GAAP EPS $5.82 (-0.7%), adjusted EPS $14.40 (+9.6%).","FY25 adjusted operating margin up 80 bps to 25.0%; adjusted gross margin up 140 bps.","Returned $2.2B to shareholders in FY25 via dividends and share repurchases.","Biosciences/Diagnostic Solutions combination with Waters Corp on track to close near end of Q1 CY2026."],"consensus_eps_estimate":2.8405,"consensus_eps_actual":5.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":21840000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117411,"accession_number":"0001628280-25-045106","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"BD reports prelim Q4 rev $5.9B (+8.3%); CFO DelOrefice to depart Dec 5; Roque interim CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 revenue ~$5.9B, up 8.3% reported, 3.9% organic; FY revenue ~$21.8B, up 8.2% reported, 2.9% organic.","CFO Chris DelOrefice resigns effective Dec 5, 2025 to pursue new opportunity; departure not due to disagreement.","Vitor Roque, SVP Finance, named interim CFO effective upon DelOrefice's departure; permanent search underway.","FY2025 adjusted diluted EPS expected at or above midpoint of prior guidance.","Headwinds in Pharma Systems vaccines and Biosciences academic/govt research; strong growth in Interventional, APM, Med Delivery Solutions."],"consensus_eps_estimate":2.8405,"consensus_eps_actual":5.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":21840000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133823,"accession_number":"0001140361-25-035307","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"BDX enters into $2.75B revolving credit facility due 2030","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2.75B senior unsecured revolving credit facility, with $100M letter of credit and $236M swingline subfacilities.","Facility expires September 2030, extendable for up to two additional one-year periods.","Leverage ratio covenant: max 4.25:1.00 (or 4.75:1.00 for five quarters post material acquisition).","Borrowing rates based on Term SOFR plus Applicable Margin ranging from 0.80% to 1.30%.","Facility replaces prior 2023 credit agreement; general corporate purposes; BDX subsidiary co-borrower."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133822,"accession_number":"0000010795-25-000069","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q3 revenue $5.5B (+10.4%); adjusted EPS $3.68; raises FY guidance to $14.30-$14.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $5.5B, up 10.4% as reported and 3.0% organic; GAAP EPS $2.00, adjusted EPS $3.68.","GAAP gross margin up 160 bps; adjusted gross margin up 50 bps; GAAP operating income up 46.6%.","Company raises full-year adjusted diluted EPS guidance to $14.30-$14.45 (up $0.18 at midpoint); reaffirms organic revenue growth guidance.","Expects to complete remaining $250M of $1B share buyback commitment by end of fiscal 2025.","In July, announced definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters Corporation."],"consensus_eps_estimate":3.9618,"consensus_eps_actual":4.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":15949000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133821,"accession_number":"0001193125-25-158797","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BD to spin off Biosciences/Diagnostics, merge with Waters for $4B cash plus 39.2% stake","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["BD receives $4B cash from SpinCo; BD shareholders get 39.2% of Waters post-merger; Waters holders get 60.8%.","Transaction structured as Reverse Morris Trust: spin-off of SpinCo then merger with Waters subsidiary.","Waters to pay $733M termination fee if deal falls under certain conditions; closing targeted by July 13, 2026.","Conditions include HSR clearance, IRS private letter ruling, Waters shareholder approval, and financing completion.","Post-closing Waters board to have 11-12 members; BD to designate 1-2 directors, Waters designates 10."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133820,"accession_number":"0001193125-25-158404","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BD to combine its Biosciences & Diagnostic Solutions with Waters in ~$17.5B RMT transaction","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transaction valued at ~$17.5B; BD shareholders to own ~39.2% of combined company; Waters ~60.8%.","Pro forma 2025E revenue ~$6.5B, adjusted EBITDA ~$2.0B; mid-to-high single-digit revenue growth expected.","Anticipated ~$345M annualized EBITDA synergies by 2030: ~$200M cost synergies by year 3, ~$290M revenue synergies by year 5.","BD to receive ~$4B cash distribution pre-close; at least half allocated to share repurchases, remainder for debt repayment.","Expected close around end of Q1 2026; subject to regulatory approvals and Waters shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150557,"accession_number":"0000010795-25-000049","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BD settles derivative suit for $9M from D&O insurance; adopts governance changes","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["D&O insurers will pay $9M to BD to settle derivative claims over Alaris pump disclosures.","BD agrees to adopt corporate governance modifications within 60 days of court approval.","Derivative actions alleged false statements on Alaris pump defects between Nov 2019 and Feb 2020.","Settlement hearing set for Aug 11, 2025 in NJ federal court; no admission of liability.","Defendants denied all wrongdoing; settlement avoids further litigation costs and risks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150556,"accession_number":"0000010795-25-000041","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BDX amends by-laws to update advance notice requirements for shareholder nominations and business","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended Article II, Section 2.D. to revise procedural and disclosure requirements for nominations and other business at annual meetings.","Changes incorporate timing and information requirements under Exchange Act Rule 14a-19.","Also updated defined terms, order of business provision, and officer appointment provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150555,"accession_number":"0000010795-25-000036","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q2 fiscal 2025: Revenue $5.27B (+4.5%), GAAP EPS $1.07 (down 42% YoY), adj. EPS $3.35","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue increased 4.5% as reported to $5.272B; organic growth 0.9%, currency-neutral growth 6.0%.","GAAP diluted EPS $1.07, down 42.2% YoY; adjusted diluted EPS $3.35, up 5.7% YoY.","Company updates full-year fiscal 2025 guidance and provides estimated tariff impact; specific numbers not detailed.","Announces intention to invest $2.5B in U.S. manufacturing capacity over next 5 years.","Business highlights include FDA clearances for Phasix ST Umbilical Hernia Patch and advanced microbiology solution."],"consensus_eps_estimate":3.4352,"consensus_eps_actual":2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":10440000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169523,"accession_number":"0000010795-25-000025","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BD elects Gregory J. Hayes to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective March 26, 2025, Gregory J. Hayes elected to BD's Board, expanding size from 11 to 12 members.","Hayes will serve on Audit Committee and Compensation and Human Capital Committee.","Board determined Hayes is independent under NYSE rules and BD's governance guidelines.","Hayes receives prorated restricted stock units valued at $180,836 covering term to 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169522,"accession_number":"0000010795-25-000019","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BD beats Q1 estimates, announces plan to separate Biosciences and Diagnostic Solutions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 revenue $5.2B (+9.8% reported, +3.9% organic); adj. EPS $3.43 (+28.0% YoY); GAAP EPS $1.04.","Company raised FY25 adjusted diluted EPS guidance at midpoint; completed $750M share repurchase.","BD board authorized separation of Biosciences and Diagnostic Solutions; target completion in fiscal 2026.","New BD (post-separation) expected FY24 revenue ~$17.8B; separated business ~$3.4B with ~30% adj. EBITDA margins.","Investor Day (Feb 26, 2025) postponed; company to provide update closer to separation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169521,"accession_number":"0000010795-25-000011","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"BD shareholders elect all 11 director nominees, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 director nominees elected with >90% support; highest vote for Carrie L. Byington (233.5M for).","Ernst & Young ratified as independent auditor for FY2025 with 235.2M for, 20.2M against.","Advisory vote on executive compensation approved with 208.4M for, 25.7M against, 622k abstain.","Broker non-votes of 21.2M on director elections and say-on-pay proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169520,"accession_number":"0000010795-25-000005","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BD appoints Pamela Spikner as Chief Accounting Officer and Controller effective Jan 20, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pamela Spikner named SVP, Chief Accounting Officer and Controller, effective January 20, 2025.","Spikner previously served as CAO of R1 RCM since July 2021; earlier roles at Hill-Rom and Exelon.","She will report to EVP/CFO Chris DelOrefice; DelOrefice remains interim principal accounting officer until BD files Q1 FY2025 10-Q.","Spikner is a CPA and CIA, holds a B.S. in Accounting from Indiana University of Pennsylvania."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186571,"accession_number":"0000010795-24-000078","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q4 FY2024 revenue $5.4B (+6.9%), adjusted EPS $3.81 (+11.4%); issues FY25 EPS guidance $14.25-$14.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $5.4B, +6.9% as reported; GAAP EPS $1.45 (vs $0.53), adjusted EPS $3.81 (vs $3.42).","FY24 revenue $20.2B, +4.2%; adjusted EPS $13.14 (+7.6%); free cash flow $3.1B (+47.4%).","FY25 guidance: organic revenue growth 4.0-4.5%; adjusted diluted EPS $14.25-$14.60 (midpoint ~10% growth).","Completed acquisition of Edwards Lifesciences' Critical Care product group, expanding smart connected care portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":5.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":20178000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186570,"accession_number":"0000010795-24-000071","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BD settles vast majority of hernia litigation for amount within existing reserve, no incremental charge","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement covers cases in Rhode Island consolidated litigation and federal MDL in Ohio; no admission of liability.","Aggregate payment within current product litigation reserve, already recorded as liability, no incremental P&L charge.","Multi-year payment structured within BD's previously communicated free cash flow goals and capital allocation.","BD will continue to defend cases not covered by this settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203147,"accession_number":"0000950103-24-012970","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BDX reassigns Thomas Spoerel to SVP, CFO Regions; DelOrefice interim principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Aug. 30, 2024, Thomas Spoerel becomes SVP, CFO Regions, leading finance integration for Edwards Critical Care acquisition.","Spoerel steps down as principal accounting officer; Christopher DelOrefice (EVP, CFO) assumes interim principal accounting officer role.","Reallocation supports finance integration of previously announced Edwards Life Sciences Critical Care product group deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203146,"accession_number":"0000010795-24-000064","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q3 adjusted EPS $3.50 beats, raises FY24 guidance; acquires Edwards Critical Care for $4.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.99B as reported, $5.057B adjusted; organic revenue growth 5.2% YoY.","GAAP diluted EPS $1.68 (+23.5% YoY); adjusted diluted EPS $3.50 (+18.2% YoY).","Year-to-date free cash flow $2.2B, up over 100% YoY.","FY2024 adjusted EPS guidance raised to $13.05-$13.15; organic revenue growth guidance 5.0%-5.25%.","Announced agreement to acquire Edwards Lifesciences' Critical Care Product Group for $4.2B."],"consensus_eps_estimate":null,"consensus_eps_actual":4.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":14741000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203145,"accession_number":"0001140361-24-032969","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Becton Dickinson extends $2.75B revolving credit facility maturity to September 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Lenders consented to one-year extension of commitment termination date to September 24, 2027.","Senior unsecured revolving facility provides $2.75B, including $100M letter of credit and $194M swingline subfacilities.","Borrowings may be used for general corporate purposes; BD Euro Finance is an authorized borrower.","Leverage ratio covenant set at 4.25:1.00 (4.75:1.00 for four quarters after a material acquisition).","Facility may be increased by up to $500M with additional lender commitments, to a total of $3.25B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219449,"accession_number":"0001140361-24-029309","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"BD issues €1.8B + $600M notes to fund Edwards Critical Care acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€1.0B 3.828% notes due 2032, €800M 4.029% notes due 2036, $600M 5.081% notes due 2029 issued June 7.","Net proceeds, with commercial paper and cash, to fund cash consideration for Edwards Lifesciences Critical Care buy.","If acquisition not closed by June 3, 2025, notes subject to special mandatory redemption at 101% of par.","Proceeds not escrowed; issuances not conditioned on deal completion.","BD fully guarantees Becton Finance €800M notes; all notes are senior unsecured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219448,"accession_number":"0000010795-24-000044","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BD to acquire Edwards Lifesciences' Critical Care for $4.2B in cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition price of $4.2B in cash; expected to close by end of calendar 2024, subject to regulatory approvals.","Critical Care generated >$900M revenue in 2023; BD expects 6-7% growth, >60% adjusted gross margin, >25% adjusted operating margin.","Funded with ~$1B cash and ~$3.2B new debt; net leverage ~3x at close, targeting 2.5x within 12-18 months via free cash flow.","Transaction immediately accretive to BD revenue growth, adjusted gross/operating margins, and adjusted EPS.","Critical Care to operate as separate business unit within BD Medical, led by Katie Szyman, based in Irvine, CA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219447,"accession_number":"0000010795-24-000036","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q2 revenue $5.0B (+4.6%), adj. EPS $3.17 (+10.8%); raises FY24 adjusted EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $5,045M (+4.6% reported, +5.7% organic); GAAP diluted EPS $1.85 (+20.9%), adjusted EPS $3.17 (+10.8%).","Year-to-date Cash from Ops $1.4B; Free Cash Flow $1.1B, up >$900M YoY.","Company raises full-year adjusted EPS guidance and affirms organic revenue growth forecast.","BD Medical increasing domestic syringe production after FDA safety communication on non-BD syringes.","BD Life Sciences launched three- and four-laser additions to BD FACSDiscover S8 Cell Sorter family."],"consensus_eps_estimate":null,"consensus_eps_actual":2.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":9751000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239285,"accession_number":"0000010795-24-000024","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BD Life Sciences President Dave Hickey to retire effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dave Hickey, EVP and President of Life Sciences segment, announced retirement effective July 1, 2024.","Hickey held the role since January 2021; previously president of Integrated Diagnostic Solutions and Diagnostic Systems.","BD intends to name a successor prior to his retirement date.","Hickey joined BD in 2014 and led development of rapid and molecular COVID-19 diagnostic tests.","No financial or guidance changes disclosed in connection with the retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239284,"accession_number":"0001140361-24-006440","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"BD issues €750M 3.519% notes and $1.175B USD notes (4.874%/5.110%) to refinance 2024 debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €750M 3.519% Notes due Feb 8, 2031 in underwritten public offering.","Issued $625M 4.874% Notes due 2029 and $550M 5.110% Notes due 2034.","Net proceeds to repay $144M 3.875% Notes, $998M 3.363% Notes, and $875M 3.734% Notes all maturing in 2024.","Euro notes callable at make-whole plus 20 bps; USD notes callable at Treasury rate plus 15 bps before par call dates.","Pending final use, proceeds may be temporarily used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239283,"accession_number":"0001140361-24-005880","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BD issues $1.175B USD notes and €750M EUR notes to refinance 2024 maturities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$625M 4.874% notes due 2029 and $550M 5.110% notes due 2034 issued in USD offering.","€750M 3.519% notes due 2031 issued in EUR offering.","Proceeds to repay $144M 3.875% notes, $998M 3.363% notes, and $875M 3.734% notes (2024 maturities).","Underwriters include Barclays, BNP Paribas, Citigroup, J.P. Morgan, and Morgan Stanley; closing expected Feb 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239282,"accession_number":"0000010795-24-000015","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q1 revenue $4.7B (+2.6% YoY), GAAP EPS $0.96, adj. EPS $2.68; raises FY2024 guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $4,706M, up 2.6% as reported, 2.4% organic; currency-neutral growth 1.6%.","GAAP diluted EPS $0.96 vs. $1.70 prior year; adjusted diluted EPS $2.68 vs. $2.98.","Company raises full-year adjusted EPS guidance and midpoint of organic revenue growth guidance.","BD Medical launched SiteRite 9 Ultrasound System; BD Life Sciences received FDA clearance for MiniDraw Capillary Blood Collection System.","BD signed World Economic Forum's Zero Health Gaps Pledge, reinforcing health equity commitment."],"consensus_eps_estimate":null,"consensus_eps_actual":0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":4706000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239281,"accession_number":"0000010795-24-000006","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"BD shareholders elect all 11 director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 11 board nominees elected with majority support; highest vote For: Joanne Waldstreicher (238.3M), lowest: Jeffrey Henderson (217.3M).","Ratification of Ernst & Young as FY2024 auditor: 241.7M For, 14.9M Against, 2.8M Abstain.","Advisory vote on named executive officer compensation approved: 220.8M For, 17.7M Against, 1.7M Abstain.","Broker non-votes ranged from 19.2M on director elections and say-on-pay; N/A for auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256787,"accession_number":"0000010795-23-000127","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BD files settlement docs for $85M class action over infusion pump statements","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement of $85M to resolve class action claims against BD and officers; no admission of liability.","Court approval sought; settlement does not resolve pending derivative actions (meritorious defenses asserted).","Amount adequately reserved and deemed not material to BD's consolidated financial results or cash flow.","Lawsuit originally filed Feb 2020 in U.S. District Court for District of New Jersey."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256786,"accession_number":"0000010795-23-000109","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BD adopts policy capping executive cash severance at 2.99x salary plus bonus without shareholder vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Policy prohibits new executive severance agreements exceeding 2.99 times base salary plus target bonus unless shareholder ratified.","Applies to officers designated under Rule 16a-1(f); covers cash severance, non-compete payments, and tax gross-ups.","Amendments that increase cash severance for existing agreements also require shareholder ratification; ordinary salary increases excluded.","Board delegated authority to Compensation Committee for amendments and interpretations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256785,"accession_number":"0000010795-23-000087","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q4 revenue $5.1B up 6.8%; adjusted EPS $3.42 beats; guides FY24 organic growth 5.75%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue of $5.1B, +6.8% as reported, +5.9% currency-neutral; base business organic growth 7.0%.","Q4 GAAP diluted EPS from continuing ops $0.53; adjusted EPS $3.42, up 24.4% YoY.","FY23 revenue $19.4B (+2.7% as reported); GAAP EPS $5.10, adjusted EPS $12.21.","FY24 organic revenue growth guidance: 5.25%-6.25% (midpoint 5.75%).","Company announces 52nd consecutive year of dividend increases (specific amount not yet disclosed)."],"consensus_eps_estimate":null,"consensus_eps_actual":4.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":19372000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274148,"accession_number":"0000010795-23-000081","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"BDX amends bylaws to tighten advance-notice rules for shareholder nominations and proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended By-laws effective Sept 19, 2023, enhance disclosure requirements for director nominations and proposals.","Shareholders must maintain ownership of shares from notice date through the annual meeting date.","Shareholders soliciting proxies must use a non-white proxy card; white card reserved for Board's exclusive use.","Also updated provisions on quorum, conduct of meetings, and made conforming/clarifying revisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274147,"accession_number":"0000010795-23-000072","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BD Q3 revenue $4.88B up 5.1%, adjusted EPS $2.96 up 11.3%, raises FY revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $4.88B, up 5.1% as reported, 6.3% currency-neutral; base revenue growth 6.7% as reported.","GAAP diluted EPS $1.36; adjusted diluted EPS $2.96 vs $2.66 YoY, up 11.3%.","Raised full-year base organic revenue growth guidance; maintained full-year adjusted EPS guidance.","Received FDA 510(k) clearance for updated BD Alaris Infusion System, a key BD 2025 milestone.","Completed sale of Surgical Instrumentation platform to STERIS for $540M."],"consensus_eps_estimate":null,"consensus_eps_actual":4.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":14285000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274146,"accession_number":"0000010795-23-000060","cik":10795,"company_name":"BECTON DICKINSON & CO","ticker":"BDX","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BD elects Dr. Joanne Waldstreicher to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Waldstreicher elected effective July 24, 2023; will serve on Corporate Governance and Nominating, and Quality and Regulatory committees.","Board determined Dr. Waldstreicher is independent under NYSE rules and BD's corporate governance guidelines.","Initial compensation: restricted stock units valued at $107,795, prorated from election to BD's 2024 Annual Meeting.","Non-management director compensation details reference BD's 2023 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":40037404515.8591,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-07-24T23:59:59+00:00|274146"}